Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: A strategy for chemokine-based multi-target-directed cancer therapy

Cancer Immunology, Immunotherapy

Volumn 59, Issue 11, 2010, Pages 1715-1726

  Wang, Ping ^a   Yang, Xiuli ^a   Xu, Wei ^a   Li, Kang ^a   Chu, Yiwei ^a   Xiong, Sidong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Anti angiogenesis; Cancer therapy; Chemokines; Chemotaxis; Combination regimen

Indexed keywords

CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; LUNG CARCINOMA; MONOTHERAPY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CARCINOMA, LEWIS LUNG; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOTAXIS; COLONIC NEOPLASMS; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; WOUND HEALING;

EID: 77958046728     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0901-6     Document Type: Article

References (40)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296. doi:10.1146/annurev.immunol.25. 022106.141609 (Pubitemid 46697910)
2. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039-2049. doi:10.1056/NEJMra0706596 (Pubitemid 351656458)
3. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83-117. doi:10.1146/annurev.immunol.021908. 132544
4. Disis ML, Bernhard H, Jaffee EM (2009) Use of tumour-responsive T cells as cancer treatment. Lancet 373(9664):673-683. doi:10.1016/S0140-6736(09)60404-9
5. Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6(7):395-404. doi:10.1038/ nrclinonc.2009.52
6. Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, Pravda E, Nahmias Y, Koirala S, Corfas G, D'Amato RJ, Folk-man J (2008) An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 26(7):799-807. doi:10.1038/nbt1415 (Pubitemid 351961454)
7. Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59(2):111-137. doi:10.3322/caac.20003
8. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540-550. doi:10.1038/nrc1388
9. Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2(3):175-184. doi:10.1038/nri748
10. Strieter RM (2001) Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2(4):285-286. doi:10.1038/86286 (Pubitemid 33706336)
11. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2(2):108-115. doi:10.1038/84209 (Pubitemid 33707927)
12. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820. doi:10.1146/annurev. immunol.24.021605.090529 (Pubitemid 46697924)
13. Fushimi T, O'Connor TP, Crystal RG (2006) Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 66(7):3513-3522. doi:10.1158/0008-5472.CAN-05-1 493
14. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J, Strieter RM (2007) Platelet factor-4 variant chemokine CXCL4l1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67(12):5940-5948. doi:10.1158/0008-5472.CAN-06-4682 (Pubitemid 46985030)
15. Chu Y, Yang X, Xu W, Wang Y, Guo Q, Xiong S (2007) In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immun-other 56(10):1539-1549. doi:10.1007/s00262-007-0296-1 (Pubitemid 47094383)
16. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184(3):981-992
17. Meiser A, Mueller A, Wise EL, McDonagh EM, Petit SJ, Saran N, Clark PC, Williams TJ, Pease JE (2008) The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 180(10):6713-6724 (180/10/1673 [pii])
18. Colvin RA, Campanella GS, Sun J, Luster AD (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279(29):30219-30227. doi:10.1074/jbc.M403595200 (Pubitemid 38937947)
19. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1):155-162
20. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278(1):289-295. doi:10.1074/jbc.M209470200 (Pubitemid 36043575)
21. Campanella GS, Lee EM, Sun J, Luster AD (2003) CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 278(19):17066-17074. doi:10.1074/jbc.M212077200 (Pubitemid 36799583)
22. Schagger H, von Jagow G (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kda. Anal Biochem 166(2):368-379
23. McColl SR, Mahalingam S, Staykova M, Tylaska LA, Fisher KE, Strick CA, Gladue RP, Neote KS, Willenborg DO (2004) Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands. Lab Invest 84(11):1418-1429. doi:10.1038/labinvest.3700155 (Pubitemid 39482159)
24. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD (2001) CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemo-attractant (CXCL11). J Immunol 167(12):7084-7093
25. Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, Alon R, Nagler A, Ben-Baruch A, Peled A (2006) Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 107(10):3821-3831. doi:10.1182/blood-2004-01-0214 (Pubitemid 43726782)
26. Zhang G, Fahmy RG, diGirolamo N, Khachigian LM (2006) Jun sirna regulates matrix metalloproteinase-2 expression, microvas-cular endothelial growth and retinal neovascularisation. J Cell Sci 119(Pt 15):3219-3226. doi:10.1242/jcs.03059 (Pubitemid 44322135)
27. Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK, Strieter RM, Dubinett SM, Sharma S (2003) EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 171(12):6457-6465
28. Zheng G, Liu S, Wang P, Xu Y, Chen A (2006) Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. Cancer Res 66(13):6793-6799. doi:10.1158/0008-5472.CAN-06-0435 (Pubitemid 44085639)
29. Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multipara-metric characterization of cell-mediated cytotoxicity. J Immunol Methods 253(1-2):177-187 (S0022-1759(01)00359-3 [pii])
30. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187(12):2009-2021
31. Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J (2007) Proteolytic processing of CXCL11 by CD13/ aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110(1):37-W. doi:10.1182/blood-2006-10-049072 (Pubitemid 47026816)
32. Cox JH, Dean RA, Roberts CR, Overall CM (2008) Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem. doi:10.1074/jbc.M800266200
33. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP (2005) CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16(6):593-609. doi:10.1016/j.cytogfr.2005.04.007 (Pubitemid 41505519)
34. Cox JH, Dean RA, Roberts CR, Overall CM (2008) Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem 283(28):19389-19399. doi:10.1074/jbc.M800266200
35. Luster AD, Greenberg SM, Leder P (1995) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182(1):219-231
36. Fernandez EJ, Lolis E (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42:469-499. doi:10.1146/annurev.pharmtox. 42.091901.115838 (Pubitemid 34160533)
37. Thompson BD, Jin Y, Wu KH, Colvin RA, Luster AD, Birnbaumer L, Wu MX (2007) Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling. J Biol Chem 282(13):9547-9555. doi:10.1074/jbc.M610931200 (Pubitemid 47104623)
38. Zhao JM, Wen YJ, Li Q, Wang YS, Wu HB, Xu JR, Chen XC, Wu Y, Fan LY, Yang HS, Liu T, Ding ZY, Du XB, Diao P, Li J, Kan B, Lei S, Deng HX, Mao YQ, Zhao X, Wei YQ (2008) A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 22(12):4272-4280. doi:10.1096/fj.08- 110049
39. Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ (2005) Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 12(11):900-912. doi:10.1038/sj.cgt. 7700854
40. Fushimi T, Kojima A, Moore MA, Crystal RG (2000) Macro-phage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105(10):1383-1393. doi:10.1172/JCI7548